In recent years, systemic therapies for the treatment of advanced TNBC have included ICIs such as atezolizumab and pembrolizumab, in combination with chemotherapy, for patients whose tumor expresses PD-L1, quantified by IHC with non-homogeneous methods in different studies. The gene discussed is CD274; the disease is neoplasm.